每周一次胰岛素:减轻糖尿病患者治疗负担的有前景方法
本文综述每周一次胰岛素的开发进展与临床证据。目前仅有胰岛素icodec和基础胰岛素Fc(胰岛素efsitora alfa)两种制剂报告了临床研究。I期和II期研究强调其降糖疗效及潜在风险与不良事件;胰岛素icodec的III期研究显示与每日基础胰岛素类似物相比低血糖风险令人安心。现有数据提示每周胰岛素也可能适用于1型糖尿病患者,尤其是依从性欠佳者。
要点
- 至少20-25%的2型糖尿病患者需要胰岛素治疗,但相当比例患者起始胰岛素后未达到充分代谢控制。
- 每周一次胰岛素为简化基础胰岛素治疗提供了独特机会,可实现良好血糖控制且低血糖风险低。
- 目前仅有胰岛素icodec和基础胰岛素Fc(胰岛素efsitora alfa)两种每周一次制剂报告了临床研究。
核心结论
- 每周一次胰岛素有望在基础胰岛素治疗领域取得重要突破,尤其对2型糖尿病患者,不仅可改善糖尿病患者生活质量,也可改善糖尿病专科医生的实践。
研究设计与样本
- 本文为综述,汇总每周一次胰岛素(胰岛素icodec和基础胰岛素Fc/胰岛素efsitora alfa)的I期、II期和III期临床研究结果。
主要发现
- 至少20-25%的2型糖尿病患者需要胰岛素治疗,且相当比例患者起始胰岛素后未达到充分代谢控制。
- 胰岛素起始后代谢控制不佳的原因包括治疗惰性、对低血糖和/或体重增加的恐惧、沟通不佳、胰岛素滴定复杂性以及注射次数多导致依从性降低。
- I期和II期研究结果强调了每周一次胰岛素在血糖水平方面的疗效以及潜在风险与不良事件。
- 胰岛素icodec的III期研究显示,与每日基础胰岛素类似物相比,低血糖风险令人安心。
- 尽管正在进行的临床试验提出了一些担忧,现有数据提示每周胰岛素也可能成为1型糖尿病患者的选择,尤其是依从性欠佳时。
临床怎么用
- 每周一次胰岛素为简化基础胰岛素治疗提供了独特机会,可实现良好血糖控制且低血糖风险低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the availability of new classes of glucose-lowering drugs that improve glycaemic levels and minimise long-term complications, at least 20-25% of people with type 2 diabetes require insulin therapy. Moreover, a substantial proportion of these individuals do not achieve adequate metabolic control following insulin initiation. This is due to several factors: therapeutic inertia, fear of hypoglycaemia and/or weight gain, poor communication, complexity of insulin titration, and the number of injections needed, with the associated reduced adherence to insulin therapy. Once-weekly insulins provide a unique opportunity to simplify basal insulin therapy and to allow good glycaemic control with a low risk of hypoglycaemia. Several approaches to developing a stable and effective once-weekly insulin have been proposed, but, to date, insulin icodec and basal insulin Fc (insulin efsitora alfa) are the only two formulations for which clinical studies have been reported. The results of Phase I and II studies emphasise both efficacy (in term of glucose levels) and potential risks and adverse events. Phase III studies involving insulin icodec are reassuring regarding the risk of hypoglycaemia compared with daily basal insulin analogues. Despite some concerns raised in ongoing clinical trials, the available data suggest that weekly insulins may also be an option for individuals with type 1 diabetes, especially when adherence is suboptimal. For the first time there is an opportunity to make an important breakthrough in basal insulin therapy, particularly in people with type 2 diabetes, and to improve not only the quality of life of people with diabetes, but also the practice of diabetologists.
引用
- Trevisan R, Conti M, Ciardullo S, et al. Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes. Diabetologia. 2024. PMID: 38679644. doi:10.1007/s00125-024-06158-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。